Access cutting-edge autoimmune liver disease treatment through this phase 1 clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this New York location
Preparing your pre-screening questions…
Access autoimmune liver disease specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related autoimmune liver disease treatment provided free
Check if you qualify for this autoimmune liver disease clinical trial in New York, NY
No-Cost Study Care
Local to New York
Convenient for NY residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
There is a significant unmet need for safe and effective therapeutic approaches to prevent immune-mediated graft injury and its complications in liver transplant (LT) recipients with autoimmune liver disease (AILD) including autoimmune hepatitis and primary sclerosing cholangitis. Siplizumab is an anti-cluster of differentiation 2 (CD2) monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key driver in the immune processes surrounding rejection and autoimmunity post LT in AILD. The purpose of this pilot, open-label phase 1 study is to determine the safety of siplizumab for induction in patients with AILD undergoing LT. Up to eight (8) subjects will receive siplizumab 0.6 mg/kg/dose on the day of transplant (Day 0) and Day 4 post-transplant, for a total of two doses. All subjects will be followed in the study for 12 months post-LT.
Sponsor: Elizabeth C. Verna
Yes, this clinical trial (NCT06455280) has an active research site in New York, NY that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for autoimmune liver disease treatment options in New York, NY, this clinical trial (NCT06455280) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced autoimmune liver disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all autoimmune liver disease clinical trials near you to find additional studies recruiting in your area.
See all multiple myeloma clinical trials recruiting in New York — not just this study.
Browse Multiple Myeloma Trials in New York →